Search results
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics - Intellia Therapeutics...
Benzinga· 1 day agoLoading... Loading... In the last three months, 4 analysts have published ratings on Intellia Therapeutics NTLA , offering a diverse range of perspectives ...
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Intellia Up on Upbeat Long-Term Angioedema Study Data - Annovis Bio (NYSE:ANVS), ALX Oncology...
Benzinga· 1 day agoIntellia Therapeutics' NTLA shares gained 10% on Jun 3 after the company reported encouraging...
Intellia Therapeutics Inc [NTLA] Insider Activity: An Update for Investors – Knox Daily
Knox Daily· 2 days agoIntellia Therapeutics Inc’s filing revealed that its EVP, General Counsel BASTA JAMES unloaded Company’s shares for reported $75778.0 on Mar 04 ’24. In ...
Intellia Therapeutics Inc (NTLA) Shares Up Despite Recent Market Volatility – News Heater
NewsHeater· 6 days agoThe stock of Intellia Therapeutics Inc (NASDAQ: NTLA) has increased by 1.98 when compared to last closing price of 21.67. Despite this, the company has ...
Why Intellia Therapeutics Shares Are Trading Higher Monday - Intellia Therapeutics (NASDAQ:NTLA)
Benzinga· 2 days agoIntellia Therapeutics, Inc. NTLA stock is moving higher Monday after the company announced long-term...
Intellia Therapeutics shares retain buy rating on strong study results By Investing.com
Investing.com· 2 days agoOn Monday, TD Cowen maintained a Buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA), a...
The 3 Best Biotech Stocks to Buy in June 2024
InvestorPlace· 4 hours agoThis was not surprising given the disparity between biotech’s high-capital requirements and rising interest rates set by the Fed. Despite these...
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial - Boston...
The Business Journals· 3 days agoOn Sunday, Intellia Therapeutics (Nasdaq: NTLA) said that its experimental gene-editing treatment...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Motley Fool via Yahoo Finance· 1 day agoJust be aware that this stock could be volatile in the meantime, depending on what breakthroughs (or...